Our findings characterize SP-1-303 as a novel, second generation, class I HDAC1 and HDAC3 selective HDAC inhibitor, exhibiting ATM activation and modulation of ER expression, resulting in substantial growth inhibition of ER+ BC cells. Here, HDAC3 is linked to breast cancer.